Memory in low-grade glioma patients treated with radiotherapy or temozolomide: a correlative analysis of EORTC study 22033-26033.
chemotherapy
low-grade glioma
memory functioning
radiotherapy
Journal
Neuro-oncology
ISSN: 1523-5866
Titre abrégé: Neuro Oncol
Pays: England
ID NLM: 100887420
Informations de publication
Date de publication:
05 05 2021
05 05 2021
Historique:
pubmed:
2
11
2020
medline:
21
5
2021
entrez:
1
11
2020
Statut:
ppublish
Résumé
EORTC study 22033-26033 showed no difference in progression-free survival between high-risk low-grade glioma receiving either radiotherapy (RT) or temozolomide (TMZ) chemotherapy alone as primary treatment. Considering the potential long-term deleterious impact of RT on memory functioning, this study aims to determine whether TMZ is associated with less impaired memory functioning. Using the Visual Verbal Learning Test (VVLT), memory functioning was evaluated at baseline and subsequently every 6 months. Minimal compliance for statistical analyses was set at 60%. Conventional indices of memory performance (VVLT Immediate Recall, Total Recall, Learning Capacity, and Delayed Recall) were used as outcome measures. Using a mixed linear model, memory functioning was compared between treatment arms and over time. Neuropsychological assessment was performed in 98 patients (53 RT, 46 TMZ). At 12 months, compliance had dropped to 66%, restricting analyses to baseline, 6 months, and 12 months. At baseline, patients in either treatment arm did not differ in memory functioning, sex, age, or educational level. Over time, patients in both arms showed improvement in Immediate Recall (P = 0.017) and total number of words recalled (Total Recall; P < 0.001, albeit with delayed improvement in RT patients (group by time; P = 0.011). Memory functioning was not associated with RT gross, clinical, or planned target volumes. In patients with high-risk low-grade glioma there is no indication that in the first year after treatment, RT has a deleterious effect on memory function compared with TMZ chemotherapy.
Sections du résumé
BACKGROUND
EORTC study 22033-26033 showed no difference in progression-free survival between high-risk low-grade glioma receiving either radiotherapy (RT) or temozolomide (TMZ) chemotherapy alone as primary treatment. Considering the potential long-term deleterious impact of RT on memory functioning, this study aims to determine whether TMZ is associated with less impaired memory functioning.
METHODS
Using the Visual Verbal Learning Test (VVLT), memory functioning was evaluated at baseline and subsequently every 6 months. Minimal compliance for statistical analyses was set at 60%. Conventional indices of memory performance (VVLT Immediate Recall, Total Recall, Learning Capacity, and Delayed Recall) were used as outcome measures. Using a mixed linear model, memory functioning was compared between treatment arms and over time.
RESULTS
Neuropsychological assessment was performed in 98 patients (53 RT, 46 TMZ). At 12 months, compliance had dropped to 66%, restricting analyses to baseline, 6 months, and 12 months. At baseline, patients in either treatment arm did not differ in memory functioning, sex, age, or educational level. Over time, patients in both arms showed improvement in Immediate Recall (P = 0.017) and total number of words recalled (Total Recall; P < 0.001, albeit with delayed improvement in RT patients (group by time; P = 0.011). Memory functioning was not associated with RT gross, clinical, or planned target volumes.
CONCLUSION
In patients with high-risk low-grade glioma there is no indication that in the first year after treatment, RT has a deleterious effect on memory function compared with TMZ chemotherapy.
Identifiants
pubmed: 33130890
pii: 5948535
doi: 10.1093/neuonc/noaa252
pmc: PMC8099470
doi:
Substances chimiques
Antineoplastic Agents, Alkylating
0
Temozolomide
YF1K15M17Y
Types de publication
Journal Article
Research Support, N.I.H., Extramural
Research Support, Non-U.S. Gov't
Langues
eng
Sous-ensembles de citation
IM
Pagination
803-811Subventions
Organisme : Cancer Research UK
ID : 6850
Pays : United Kingdom
Organisme : Department of Health
Pays : United Kingdom
Commentaires et corrections
Type : CommentIn
Informations de copyright
© The Author(s) 2020. Published by Oxford University Press on behalf of the Society for Neuro-Oncology.
Références
Lancet Neurol. 2009 Sep;8(9):810-8
pubmed: 19665931
Curr Opin Oncol. 2012 Nov;24(6):672-8
pubmed: 22913969
Lancet Oncol. 2016 Nov;17(11):1521-1532
pubmed: 27686946
Lancet Oncol. 2016 Nov;17(11):1533-1542
pubmed: 27686943
Nature. 1999 Aug 12;400(6745):671-5
pubmed: 10458162
Semin Oncol. 2004 Oct;31(5):702-13
pubmed: 15497124
J Neurooncol. 2007 May;82(3):281-8
pubmed: 17082887
Nature. 2001 May 17;411(6835):248-9
pubmed: 11357109
Acta Neuropathol. 2016 Jun;131(6):803-20
pubmed: 27157931
Int J Radiat Oncol Biol Phys. 2013 Feb 1;85(2):348-54
pubmed: 23312272
Lancet. 2009 Nov 7;374(9701):1639-51
pubmed: 19897130
J Clin Oncol. 2004 Jan 1;22(1):157-65
pubmed: 14701778
Nat Rev Clin Oncol. 2018 Feb;15(2):112-125
pubmed: 29158591
Lancet Oncol. 2009 Nov;10(11):1037-44
pubmed: 19801201
JAMA. 2016 Jul 26;316(4):401-409
pubmed: 27458945
N Engl J Med. 2016 Apr 7;374(14):1344-55
pubmed: 27050206
Lancet. 2005 Sep 17-23;366(9490):985-90
pubmed: 16168780
Neurol Med Chir (Tokyo). 2014;54(4):272-9
pubmed: 24257502
Int J Radiat Oncol Biol Phys. 2016 Feb 1;94(2):297-304
pubmed: 26853338
Int J Radiat Oncol Biol Phys. 1996 Jun 1;35(3):527-33
pubmed: 8655376
J Clin Oncol. 2014 Feb 20;32(6):535-41
pubmed: 24419119
Neurology. 2000 Apr 11;54(7):1442-8
pubmed: 10751254
J Clin Oncol. 2012 Sep 1;30(25):3065-70
pubmed: 22851558
Lancet. 2002 Nov 2;360(9343):1361-8
pubmed: 12423981
Neurology. 2001 May 22;56(10):1285-90
pubmed: 11376174
Arch Clin Neuropsychol. 2014 May;29(3):278-88
pubmed: 24695591
Neurology. 2002 Jul 9;59(1):40-8
pubmed: 12105305
Radiother Oncol. 2016 Jan;118(1):29-34
pubmed: 26806266